Syndax Pharmaceuticals Inc. (SNDX) is a renowned biopharmaceutical company with a primary focus on the development and commercialization of novel, innovative therapeutics designed to prolong and improve the lives of patients with severe or life-threatening cancers. Situated in Waltham, Massachusetts, the company was launched in 2005, with the ultimate goal of empowering patients in the fight against cancer.
Syndax Pharmaceutical's primary product candidate is Entinostat, an oral, small molecule drug that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated in several phase 1b/2 and 3 clinical trials for various types of solid tumors. The company also develops SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction that is used in the treatment of acute leukemias.
Syndax Pharmaceuticals has collaboration agreements with prestigious research institutions and pharmaceutical giants, such as Genentech, Inc., and National Cancer Institute, continuing to push boundaries in cancer therapy. In addition, the company's intellectual property holds several patents relating to its product candidates, demonstrating a robust and promising research pipeline.
The company's commitment to transforming the lives of cancer patients motivates its push towards the development of next-generation therapies that can effectively tackle advanced cancers. Its pursuits aim to satisfy the unmet medical needs, which have not been adequately covered by the current, conventional therapies.
Throughout the years, Syndax Pharmaceuticals has demonstrated a steadfast commitment to quality, innovation, and patient safety. It aspires to lead the pharma industry in offering comprehensive solutions for serious illnesses and life-threatening conditions. The team of experts at Syndax is driven both by scientific curiosity and a deep desire to bring novel therapies to people who need them the most, upholding the company's objective of ensuring healthier lives and outcomes.
Syndax's approach also encompasses a meticulous and rigorous scientific model that supports the discovery, development, and delivery of innovative cancer treatments. By remaining at the forefront of biopharmaceutical research, Syndax Pharmaceuticals Inc. continues to be a beacon of hope for countless patients and the broader medical community, as cancer's fatal global impact looms as an ever-present challenge.
With its patient-centric strategy, Syndax Pharmaceuticals Inc. continues to make significant strides forward towards pioneering advanced medications and therapeutic solutions that are set to revolutionize the treatment of severe and life-threatening illnesses.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Bank of America Corp DE has acquired a new position in Syndax Pharmaceuticals, Inc., purchasing over 4 million shares valued at approximately $88.4 million during the second quarter. This move makes Bank of America a significant holder, owning about 4.57% of Syndax Pharmaceuticals. Despite the acquisition, Syndax Pharmaceuticals reported a quarterly loss and revenue that missed analyst estimates, though analysts maintain a "Moderate Buy" consensus for the stock.
Eleven brokerages have issued a "Moderate Buy" rating for Syndax Pharmaceuticals (NASDAQ:SNDX), with an average 12-month price target of $42.30, significantly above its current trading price of $18.18. Despite this bullish analyst sentiment, the company recently missed quarterly earnings and revenue estimates, though revenue increased 91.8% year-over-year. Insider selling by the CEO in July also saw a reduction in his ownership.
WINTON GROUP Ltd significantly increased its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 642.7% in the second quarter, bringing its total holdings to 76,500 shares valued at approximately $1.67 million. Despite the company reporting a wider-than-expected quarterly loss and revenue miss, analysts maintain a "Moderate Buy" rating with an average price target of $42.30. Several institutional investors also initiated or expanded their positions in Syndax Pharmaceuticals, while CEO Michael Metzger sold a portion of his shares.
Squarepoint Ops LLC significantly increased its stake in Syndax Pharmaceuticals Inc. by 104% in the second quarter, now owning 370,317 shares valued at $8.1 million. Despite this increased institutional interest, the company reported a quarterly loss and revenue below analyst expectations, and several firms have lowered their price targets, although the consensus rating remains "Moderate Buy." CEO Michael Metzger also sold a substantial number of shares in July.
Legal & General Group Plc has acquired a significant stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the second quarter, purchasing 65,483 shares valued at approximately $1.43 million. This comes as several other institutional investors also adjusted their positions in the company. Despite Syndax Pharmaceuticals reporting a quarterly loss that missed analyst expectations, revenue increased by 91.8% year-over-year, and analysts generally maintain a "Moderate Buy" rating with a target price significantly above the current trading price.